Fortis Healthcare Ltd. (FORTIS) AI Stock Analysis

• Market Cap: ₹730.20B
• Dividend Yield: 0.1%
• Average Volume (3M): 42.00K
• Price to Earnings (P/E): 84.1
• Beta (1Y): 0.99
• Revenue Growth: 14.04%
• EPS Growth: 32.99%
• Country: IN
• Employees: 12,088
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 3.40
• Shares Outstanding: 754,958,100
• 10 Day Avg. Volume: 40,673
• 30 Day Avg. Volume: 42,000
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹917.50
• Price Target Upside: -5.21% Downside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 75 Outperform
• Price Target: ₹905.00 ▼(-6.50% Downside)

Fortis Healthcare Ltd. receives a strong overall score due to its robust financial performance and favorable technical analysis. The company's consistent revenue growth, improved profitability, and positive market momentum are key strengths. However, the high valuation suggests potential overvaluation, which is a risk factor for investors.

Fortis Healthcare Ltd. Business Overview & Revenue Model

Company Description

Fortis Healthcare Limited, an integrated healthcare delivery service provider, offers secondary, tertiary, and quaternary care in India, the United Arab Emirates, Sri Lanka, and internationally. Its healthcare verticals comprise hospitals, diagnostics, and day care specialty facilities. The company offers services in the areas of cardiac science, cosmetology, dental science, dermatology, diabetes/endocrinology, emergency medicine, ENT, foetal medicine, gastroenterology and hepatology science, general surgery, haematology, infertility medicine, internal medicine, mental health and behavioral science, nephrology, neuro surgery, neurointerventional radiology, neurology, obstetrics and gynaecology, oncology, ophthalmology, orthopedics, pediatrics, physiotherapy and rehabilitation, plastic and reconstructive surgery, pulmonology, radiology, rheumatology, thoracic surgery, transplantation medicine, urology, and other support specialties. As of March 31, 2022, it operated a network of 26 hospitals with approximately 4,300 operational beds. The company also operates approximately 426 diagnostics centers and laboratories; and 2,550 collection centers. The company was incorporated in 1996 and is based in Gurugram, India.

How the Company Makes Money

Fortis Healthcare Ltd. generates revenue primarily through its network of hospitals and healthcare facilities by providing medical and healthcare services to patients. The company's key revenue streams include inpatient and outpatient services, diagnostic services, and specialized medical treatments. Inpatient services generally involve hospital stays for surgical procedures, intensive care, and other medical treatments, which contribute significantly to the company's earnings. Outpatient services include consultations, day-care surgeries, and routine check-ups. Additionally, Fortis Healthcare earns revenue from its diagnostics division, which offers a range of laboratory and imaging services. The company also benefits from strategic partnerships and collaborations with international healthcare providers, which enhance its service offerings and extend its market reach. Revenue is further supported by health insurance tie-ups, making healthcare services accessible to a broader patient base.

Fortis Healthcare Ltd. Financial Statement Overview

Summary

Fortis Healthcare Ltd. demonstrates strong financial performance with consistent revenue growth and improved profitability. The income statement shows robust gross and net profit margins. The balance sheet is stable with a healthy equity ratio, though total debt levels require monitoring. Cash flow is positive with strong cash-generating ability, despite some volatility in capital expenditures.

Income Statement

Fortis Healthcare Ltd. has demonstrated a strong income statement performance with consistent revenue growth, particularly from 2021 to 2025. The gross profit margin has remained robust, averaging above 40% in recent years, indicating effective cost management. Net profit margins have improved significantly, turning from negative to positive, showcasing enhanced profitability. EBIT and EBITDA margins have also seen notable improvements, indicating operational efficiency gains.

Balance Sheet

The company's balance sheet is solid with a healthy equity ratio, reflecting financial stability. The debt-to-equity ratio has been improving, suggesting prudent financial management and reduced leverage risk. Return on equity has increased, highlighting better efficiency in generating profits from shareholders' equity. However, the total debt level remains a consideration, though manageable given the company's growth trajectory.

Cash Flow

Fortis Healthcare Ltd. exhibits a positive cash flow trajectory, with significant growth in free cash flow over the years. The operating cash flow to net income ratio indicates strong cash-generating ability relative to accounting profits. However, fluctuations in capital expenditures and investing cash flows highlight potential volatility in future cash flows. Overall, cash flow management appears effective, supporting the company's expansion and operational needs.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	77.83B	77.83B	68.35B	62.98B	56.39B	39.61B
Gross Profit	36.48B	31.55B	22.95B	35.31B	42.21B	21.17B
EBITDA	16.00B	15.88B	13.07B	12.29B	14.03B	4.44B
Net Income	7.74B	7.74B	5.99B	5.89B	5.55B	-1.10B
Balance Sheet
Total Assets	136.92B	136.92B	132.89B	124.34B	118.85B	111.55B
Cash, Cash Equivalents and Short-Term Investments	5.08B	5.08B	6.00B	3.94B	4.13B	4.16B
Total Debt	24.75B	24.75B	11.55B	9.26B	12.55B	15.31B
Total Liabilities	45.22B	45.22B	47.33B	43.33B	48.76B	44.37B
Stockholders Equity	89.17B	89.17B	76.63B	72.42B	61.78B	61.20B
Cash Flow
Free Cash Flow	0.00	5.77B	1.58B	3.75B	6.50B	2.67B
Operating Cash Flow	0.00	14.24B	11.00B	8.22B	8.65B	4.85B
Investing Cash Flow	0.00	-7.79B	-9.21B	-3.74B	-5.14B	-1.35B
Financing Cash Flow	0.00	-7.14B	-864.58M	-4.71B	-5.17B	-1.43B

Fortis Healthcare Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 967.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FORTIS, the sentiment is Positive. The current price of 967.9 is above the 20-day moving average (MA) of 952.78, above the 50-day MA of 905.98, and above the 200-day MA of 739.17, indicating a bullish trend. The MACD of 16.82 indicates Positive momentum. The RSI at 58.70 is Neutral, neither overbought nor oversold. The STOCH value of 48.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:FORTIS.

Fortis Healthcare Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FORTIS	75 Outperform	₹730.20B	84.07	―	0.10%	14.04%	32.99%
APOLLOHOSP	73 Outperform	1.11T	70.69	17.61%	0.25%	14.31%	51.71%
LALPATHLAB	70 Outperform	284.20B	55.09	22.42%	0.72%	10.57%	34.11%
METROPOLIS	66 Neutral	107.86B	69.41	10.89%	―	12.86%	10.42%
MANKIND	66 Neutral	1.07T	55.74	13.89%	0.04%	21.66%	-4.92%
NH	65 Neutral	355.44B	45.05	21.79%	0.26%	12.09%	-2.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Fortis Healthcare Ltd. Corporate Events

Fortis Healthcare Reports Debt Securities Issuance

Fortis Healthcare Limited has reported details of its debt securities issued through private placement, as per the SEBI Master Circular. The company has issued debt securities amounting to a total of 1,550 Crore INR, with a coupon rate of 8.486% for the first year, which will be reset annually. This announcement is significant for stakeholders as it reflects Fortis Healthcare’s financial strategies and commitments in the debt market, potentially impacting its financial stability and market positioning.